Treatment Considerations in KRAS NSCLC

 

Nebraska Oncology Society
V

NOS ASCO® 2023 Review: Targeting Advanced KRAS and EGFR Mutations in NSCLC

By Nebraska Oncology Society FEATURING Vincent Lam
By Nebraska Oncology Society FEATURING Vincent Lam
86 views
July 3, 2023
0 Comments
Login to view comments. Click here to Login
Treatment Considerations in KRAS NSCLC
04:42
GRACE

NSCLC Panel Discussion: Should a Patient With High PD-L1 Wait for Ge…

Feat. K. Higgins, A. Desai, J. Lin, J. Reuss, P. Iyengar
06:29
Insights from 2023 WCLC

WCLC 2023 Insights: "KRYSTAL-1 - Two-Year Follow-Up of Adagrasi…

Feat. S. Gadgeel
21:16
GRACE

Targeted Therapies in Lung Cancer 2023: Translating Cancer Discovery…

Feat. J. Sabari
14:45
Yale Cancer Center

KRAS G12C NSCLC Treatment Approach: Surveying OS Data, CNS Activity,…

Feat. A. Nassar
07:34
Marcelo Negrao

Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Tr…

17:07
Nebraska Oncology Society

NOS ASCO® 2023 Review: Targeting Advanced KRAS and EGFR Mutations in…

Feat. V. Lam
18:14
Janakiraman Subramanian

Understanding KRAS G12C Positive Lung Cancer

09:17
Shirish Gadgeel

The Data on Novel KRAS G12C Inhibitors: Focus on Adagrasib

33:14
Benjamin Herzberg

Direct KRAS Inhibition in NSCLC: Past, Present, and Future